RE:RE:RE:RE:RE:Test numbersI agree...
The stopping of the Billing Process was not a surprise. We all knew that the billing process was stopped on March 31,2019 as stated on Sedar.com Aug 14,2019.
On the same date(Aug14,2019) J.Tripp said " The billing process was to be restarted in Q3, 2019 ". And that is exactly what J.Tripp did a few weeks ago.
We can't expect sales to be computed without an active Billing Process. From now on the Billing Process is active, we should see the difference.
davewho wrote: James made it very clear in both the CC and the interview last week that in house billing has only just started the end of Oct. Rev umbers aren't going to show up until Q4 and Q1. He also said they have been approached by 2 investment banks in the US and one in Canada. So why are big investments banks even interested? They obviously can see the potential especially when Aristotle is validated. He also said they fully expect to seek FDA approval for Artistotle. Also ColonSentry2 will be part of Aristotle. There are many things going on that we never see. Insiders know but we don't.